Actuate Therapeutics, Inc. (ACTU) shareholders
Close on Nov 13, 2026Market cap $6.85MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Aaron G.L. Fletcher Joint filing with Bios Advisors Gp, LLC (49.50%), Bios Capital Management, LP (49.50%) and 9 more | 10,267,232 | 49.80% | 13D (active) amendment | Jun 27, 2025 |
| Brendan O'Neil Joint filing with Hexstone Capital LLC (7.70%) | 4,225,352 | 7.70% | 13G (passive) | Oct 27, 2026 |
| Voss Capital, LP Joint filing with Cocke Travis W. (7.70%) | 1,814,263 | 7.70% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ACTU | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BIOS Capital Management, LP | 10,049,996 | 41.85% | $15.38M | – | 36.90% |
| Voss Capital, LLC | 1,725,000 | 7.18% | $2.64M | – | 0.12% |
| Vanguard Capital Management LLC | 393,433 | 1.64% | $601.95K | −7,096 | 0.00% |
| Aqr Capital Management LLC | 127,493 | 0.53% | $195.06K | +100,384 | 0.00% |
| Geode Capital Management, LLC | 112,554 | 0.47% | $172.21K | −115,777 | 0.00% |
| Texas Capital Bank Wealth Management Services Inc | 102,612 | 0.43% | $157.00K | +8,020 | 0.01% |
| Palogic Value Management, L.P. | 100,000 | 0.42% | $153.00K | – | 0.05% |
| Millennium Management LLC | 96,684 | 0.40% | $147.93K | New | 0.00% |
| BlackRock, Inc. | 90,035 | 0.37% | $137.75K | −337,118 | 0.00% |
| ABS Investment Management LLC | 73,186 | 0.30% | $111.98K | New | 0.07% |
| ABS Direct Equity Fund LLC | 73,186 | 0.30% | $111.98K | +23,186 | 0.07% |
| Vanguard Fiduciary Trust Co | 54,497 | 0.23% | $83.38K | −8,095 | 0.00% |
| Rock Creek Group, LP | 39,263 | 0.16% | $60.07K | – | 0.01% |
| Jane Street Group, LLC | 39,132 | 0.16% | $59.87K | New | 0.00% |
| HighTower Advisors, LLC | 36,461 | 0.15% | $55.79K | New | 0.00% |
| Goldman Sachs Group Inc | 35,498 | 0.15% | $54.31K | +23,090 | 0.00% |
| Sfmg, LLC | 33,000 | 0.14% | $50.49K | – | 0.00% |
| Susquehanna International Group, Llp | 28,182 | 0.12% | $43.12K | New | 0.00% |
| Bridgeway Capital Management, LLC | 23,482 | 0.10% | $35.93K | −7,500 | 0.00% |
| State Street Corp | 21,850 | 0.09% | $33.43K | −44,180 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 64 | 14M | 56.3% | 18 / 18 | 20 / 14 | 1M | 1M |
| Q1 2026 | 61 | 14M | 57.7% | 22 / 20 | 10 / 4 | 1M | 0M |
| Q4 2025 | 45 | 13M | 54.6% | 8 / 21 | 9 / 6 | 1M | 0M |
| Q3 2025 | 43 | 12M | 50.1% | 7 / 17 | 11 / 2 | 1M | 0M |
| Q2 2025 | 38 | 11M | 46.7% | 21 / 12 | 2 / 8 | 1M | 0M |
| Q1 2025 | 25 | 10M | 43.3% | 9 / 10 | 1 / 3 | 0M | 0M |
| Q4 2024 | 19 | 10M | 42.1% | 13 / 1 | 2 / 4 | 10M | 0M |
| Q3 2024 | 10 | 0M | 1.6% | 10 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
59 funds held ACTU in Q1 2026, 70% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ACTU | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 287,385 | 1.20% | $439.70K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 106,048 | 0.44% | $162.25K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 51,919 | 0.22% | $104.88K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 48,395 | 0.20% | $97.76K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 38,230 | 0.16% | $58.49K | 0.00% | Jun 30, 2026 |
| Ultra-Small Company Market Fund | 23,482 | 0.10% | $35.93K | 0.02% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 15,885 | 0.07% | $32.09K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 13,591 | 0.06% | $27.45K | 0.00% | May 31, 2026 |
| iShares Russell 2000 ETF | 13,249 | 0.06% | $20.27K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 12,252 | 0.05% | $24.75K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 8,845 | 0.04% | $17.87K | 0.00% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 5,506 | 0.02% | $8.42K | 0.00% | Jun 30, 2026 |
| Small Cap Index Fund | 5,490 | 0.02% | $11.09K | 0.00% | May 31, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 1,738 | 0.01% | $2.66K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 1,700 | 0.01% | $2.60K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Daniel M. Schmitt | President, CEO and Director | 1,073,300 | 4.47% | Oct 29, 2026 |
| Andrew Paul Mazar | Chief Operating Officer | 127,250 | 0.53% | Apr 1, 2026 |
| Paul J. Lytle | Chief Financial Officer | – | – | Apr 1, 2026 |
| Kairos Venture Investments, LLC | Director | – | – | Nov 2, 2026 |
| Kairos Venture Partners II, L.P. | Director | – | – | Nov 2, 2026 |
| Kairos Venture Opportunities I, L.P. | Director | – | – | Nov 2, 2026 |
| SPV Fund LLC Kairos | Director | – | – | Nov 2, 2026 |
| Kairos-Actuate SPV, L.P. | Director | 2,487,474 | 10.36% | Nov 2, 2026 |
| James T. Demetriades | Director | – | – | Nov 2, 2026 |
| Todd S. Thomson | Director | 2,354,344 | 9.80% | Nov 2, 2026 |
| BIOS Fund II NT, LP | Director, 10% owner | – | – | Oct 30, 2026 |
| BIOS Fund I, LP | Director, 10% owner | – | – | Oct 30, 2026 |
| BIOS Fund II, LP | Director, 10% owner | 10,257,429 | 42.71% | Oct 30, 2026 |
| BIOS Fund I QP, LP | Director, 10% owner | – | – | Oct 30, 2026 |
| BIOS Fund II QP, LP | Director, 10% owner | 9,147,214 | 38.09% | Oct 30, 2026 |
| BIOS Fund III, LP | Director, 10% owner | – | – | Oct 30, 2026 |
| BIOS Fund III QP, LP | Director, 10% owner | – | – | Oct 30, 2026 |
| BIOS Fund III NT, LP | Director, 10% owner | – | – | Oct 30, 2026 |
| Bios Clinical Opportunity Fund, LP | Director, 10% owner | 1,472,797 | 6.13% | Oct 30, 2026 |
| BIOS Actuate Co-Invest II, LP | Director, 10% owner | – | – | Oct 30, 2026 |
| Bios Actuate Co-Invest III, LP | Director, 10% owner | 231,377 | 0.96% | Oct 30, 2026 |
| BIOS Actuate Co-Invest I, LP | Director, 10% owner | 10,196,456 | 42.46% | Oct 30, 2026 |
| Bios 2024 Co-Invest, LP | Director, 10% owner | 125,000 | 0.52% | Oct 30, 2026 |
| Aaron G.L. Fletcher | Director, 10% owner | – | – | May 22, 2026 |
| Amy L. Ronneberg | Director | – | – | May 22, 2026 |
| Roger Sawhney | Director | – | – | May 22, 2026 |
| Dan Zabrowski | Director | 76,348 | 0.32% | May 22, 2026 |
| Jason A. Keyes | Director | – | – | May 22, 2026 |
| Martin H. Huber Jr. | Director | – | – | May 22, 2026 |
| BIOS Advisors GP, LLC | Director, 10% owner | – | – | Jun 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Daniel M. Schmitt President, CEO and Director | Oct 28, 2026 | Buy | +140,844 | $0.35 | $50.00K | 442,560 |
| Daniel M. Schmitt President, CEO and Director | Aug 14, 2026 | Option exercise | +272,056 | – | – | 422,237 |
| Daniel M. Schmitt President, CEO and Director | Aug 14, 2026 | Tax withholding | −120,521 | $1.01 | $121.73K | 301,716 |
| Daniel M. Schmitt President, CEO and Director | Feb 13, 2026 | Option exercise | +272,055 | – | – | 272,055 |
| Daniel M. Schmitt President, CEO and Director | Feb 13, 2026 | Tax withholding | −121,874 | $4.33 | $527.71K | 150,181 |
| Todd S. Thomson Director, 10% owner | Jan 5, 2026 | Sale | −280,000 | $5.80 | $1.62M | 904,795 |
| Bios Equity COF, LP Director, 10% owner | Jun 27, 2025 | Buy | +71,428 | $7.00 | $500.00K | 196,428 |
| BIOS Actuate Co-Invest I, LP Director, 10% owner | Jun 27, 2025 | Buy | +71,428 | $7.00 | $500.00K | 196,428 |
| BIOS Fund II, LP Director, 10% owner | Jun 27, 2025 | Buy | +71,428 | $7.00 | $500.00K | 196,428 |
| BIOS Capital Management, LP Director, 10% owner | Aug 14, 2024 | Sale | −17,361 | $8.00 | $138.89K | 980,433 |
| BIOS Capital Management, LP Director, 10% owner | Aug 14, 2024 | Sale | −5,314 | $8.00 | $42.51K | 300,143 |
| BIOS Capital Management, LP Director, 10% owner | Aug 14, 2024 | Sale | −2,324 | $8.00 | $18.59K | 131,248 |
| Bios Clinical Opportunity Fund, LP Director, 10% owner | Aug 14, 2024 | Sale | −5,314 | $8.00 | $42.51K | 300,143 |
| Bios Clinical Opportunity Fund, LP Director, 10% owner | Aug 14, 2024 | Sale | −17,361 | $8.00 | $138.89K | 980,433 |
| Bios Clinical Opportunity Fund, LP Director, 10% owner | Aug 14, 2024 | Sale | −2,324 | $8.00 | $18.59K | 131,248 |
| BIOS Fund II, LP Director, 10% owner | Aug 14, 2024 | Sale | −17,361 | $8.00 | $138.89K | 980,433 |
| BIOS Fund II, LP Director, 10% owner | Aug 14, 2024 | Sale | −5,314 | $8.00 | $42.51K | 300,143 |
| BIOS Fund II, LP Director, 10% owner | Aug 14, 2024 | Sale | −2,324 | $8.00 | $18.59K | 131,248 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Sale | −18,750 | $8.00 | $150.00K | 1,184,795 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Option exercise | +28,464 | $5.27 | $150.01K | 1,203,545 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Conversion | +49,984 | – | – | 321,781 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Conversion | +24,138 | – | – | 254,735 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Conversion | +132,908 | – | – | 271,797 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Conversion | +69,445 | – | – | 1,175,081 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Conversion | +1,058,318 | – | – | 1,105,636 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Conversion | +726,163 | – | – | 726,163 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Conversion | +138,889 | – | – | 138,889 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Conversion | +230,597 | – | – | 230,597 |
| Kairos-Actuate SPV, L.P. Director | Aug 14, 2024 | Conversion | +146,870 | – | – | 873,033 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Buy | +375,000 | $8.00 | $3.00M | 1,259,427 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Option exercise | +3,528 | $5.27 | $18.59K | 133,572 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Sale | −17,361 | $9.00 | $156.25K | 980,433 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Option exercise | +26,355 | $5.27 | $138.89K | 997,794 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Sale | −5,314 | $9.00 | $47.83K | 300,143 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Option exercise | +8,068 | $5.27 | $42.52K | 305,457 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +573,394 | – | – | 573,394 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +78,267 | – | – | 404,814 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +484,638 | – | – | 2,506,667 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +74,202 | – | – | 383,791 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +2,094,650 | – | – | 2,094,650 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +326,547 | – | – | 326,547 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +2,022,029 | – | – | 2,022,029 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +309,589 | – | – | 309,589 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +44,559 | – | – | 130,044 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +332,867 | – | – | 971,439 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +101,900 | – | – | 297,389 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +147,047 | – | – | 300,749 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +23,628 | – | – | 85,485 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +176,499 | – | – | 638,572 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +54,032 | – | – | 195,489 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +153,702 | – | – | 153,702 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +61,857 | – | – | 61,857 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +462,073 | – | – | 462,073 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +141,457 | – | – | 141,457 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +307,538 | – | – | 307,538 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +525,797 | – | – | 525,797 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Buy | +125,000 | $8.00 | $1.00M | 125,000 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Sale | −2,324 | $9.00 | $20.92K | 131,248 |
| BIOS Equity Partners III, LP Director, 10% owner | Aug 14, 2024 | Conversion | +884,427 | – | – | 884,427 |
| BIOS Fund II QP, LP Director, 10% owner | Aug 14, 2024 | Conversion | +61,857 | – | – | 61,857 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Actuate Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 95,859 shares on Oct 7, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kairos Venture Partners II, L.P. Affiliate | Dec 11, 2025 | 280,000 | $2.13M | Dec 11, 2025 | Private Investment, Pre-IPO |
See a number that looks wrong?